ABSTRACT
INTRODUCTION AND OBJECTIVE: Organs from deceaseddonors who tested positive for COVID-19 were thought to be ineligible for transplantation. Despite lack of evidence showing that COVID-19 can be transmitted through urine or blood. We began to transplant kidneys from COVID-positive deceased-donors in February 2021 and this report comprises our early outcomes in this patient cohort. METHODS: From Feb 2021 to Oct 2021, 55 patients underwent kidney transplantation from 34 COVID-19 positive donors. Prior to initiating this clinical practice, formalized selection criteria for organs from COVID-19 positive deceased-donors were adopted by transplant surgeons, transplant nephrologists, and infectious disease physicians. If a deceased-donor suited these pre-determined criteria, individual kidney selection followed our usual programmatic criteria. RESULTS: The mean donor age was 34±13.7 years with a mean kidney donor profile index (KDPI) of 36.9±22.7%. All donors had at least 1 positive COVID-19 test from the nasopharyngeal ribonucleic acid swab test within a median of 4 (0-76) days prior to declaration as a deceased-donor. Extracorporeal membrane oxygenation (ECMO) was used in 6 donors. The initial and terminal mean creatinine was 1.1±1.1 mg/dl and 1.0±0.4 mg/dL. This patient cohort includes 36 male recipients and 19 female recipients. Mean age among all recipients was 51.2±13.5 years. Thirty-seven recipients (66.7%) were dialysis dependent. A similar proportion (67.3%) had received both COVID-19 vaccine doses. Delayed graft function occurred in 19.6% of the recipients. No patient tested positive for COVID-19 after surgery. At a mean follow up duration of 3.5 months, all kidney allografts are functioning, with a mean serum creatinine of 1.6±0.7 mg/dl. One patient underwent allograft nephrectomy at 1.5 months post-transplant due to Pseudomonas aeruginosa vascular infection. CONCLUSIONS: Transplantation of kidneys from COVID-19 positive donors is safe. Outcomes are comparable to kidneys from regular donors.
ABSTRACT
The proceedings contain 205 papers. The topics discussed include: waitlist outcomes for liver waitlist candidates 1-year following the implementation of MMAT/250 score;bariatric surgery associated ventricular modeling decreases need for heart transplantation;antibody response to a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: mRNA and viral vector boosters;socioeconomic deprivation of 'closed for no contact' kidney transplant referrals;designing continuous distribution for liver allocation;the impact of functional donor warm ischemia time on incidence of ischemic cholangiopathy following DCD liver transplantation;and xenogeneic cross-circulation for extracorporeal recovery of human lungs declined after ex vivo lung perfusion.